Haematologic Technologies, Inc. (HTI) is a privately-held medical device company engaged in the development, manufacturing and marketing of high-quality coagulation proteins and research reagents. The company offers purified coagulation factors, factor inhibitors, substrates, antibodies, sample collection tubes and ELISA reagents designed for use in vitro research. Its product portfolio comprises of more than 150 highly purified and well-characterized proteins such as zymogens, enzymes, cofactors, and inhibitors and also a complete range of monoclonal and polyclonal antibodies. Additionally, the company offers services including custom protein purification, protein modification, assay development, contract manufacturing and contract research. It sells its products through a wide network of distributors worldwide. HTI is headquartered in Vermont, the US.